Cd38 monoclonal antibody antigens cd38. Medical search. Frequent questions

ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. (drugs.com)
Elranatamab is an antibody that binds to both CD3 on T-cells and B-cell maturation antigen (BCMA), which are expressed on the surface of multiple myeloma cells. (medscape.com)
Received B-cell maturation antigen (BCMA)-targeted therapy. (survivornet.com)
B-cell maturation antigen (BCMA), a member of the tumor necrosis issue receptor superfamily, is universally expressed by regular and neoplastic plasma cells and performs a essential function within the proliferation, survival and tumor development in a number of myeloma (MM). B-cell activating issue (BAFF) and a proliferation-inducing ligand (APRIL) have been acknowledged as proliferation ligands for BCMA within the bone marrow microenvironment. (bd-academy.org)
It is a bispecific B-cell maturation antigen (BCMA)-a directed cluster of differentiation 3 (CD3) T-cell engager indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (vativorx.com)
Most of the MM CAR-T cell therapies that are under investigation are directed against the B-cell maturation antigen (BCMA) - a protein found on the surface of most myeloma cells. (lls.org)
This distinction for teclistamab, an off-the-shelf, T-cell redirecting, a bispecific antibody targeting both BCMA and CD3 receptors, follows a PRIME designation from the EMA received earlier this year. (mississippichronicle.com)
Several antigens have been used as targets for CAR-T cell therapy against MM, including B cell maturation antigen (BCMA), CD19, CD138, signaling lymphocytic activation molecule 7 (SLAM7), and immunoglobulin light chains. (biomedcentral.com)
Two main advantages of BCMA as an antigen for CAR-T therapy are the potential reduction of on-target/off-tumor toxicity and the lack of antigen-dependent reduction in CAR-T cell expansion [ 16 ]. (biomedcentral.com)

Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. (wikipedia.org)
Multiple myeloma may develop from monoclonal gammopathy of undetermined significance (MGUS) that progresses to smoldering myeloma. (wikipedia.org)
Multiple myeloma is diagnosed based on blood or urine tests finding abnormal antibody proteins - (often using electrophoretic techniques revealing the presence of a monoclonal spike in the results - termed an m-spike), bone marrow biopsy finding cancerous plasma cells, and medical imaging finding bone lesions. (wikipedia.org)
4-9 Patients with relapsed or refractory multiple myeloma that have been exposed to all three major drug classes (triple-class exposed), including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, tend to demonstrate poor clinical outcomes with very low response rates (20% to 30%), short duration of response (2 to 4 months) and poor survival. (drugs.com)
Elranatamab is indicated for adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (medscape.com)
These initial results encouraged us to undertake preclinical investigations with immunotoxins directed against the B-cell restricted CD19 antigen for B-lymphoid tumors and against the CD38 molecule for multiple myeloma. (atsbio.com)
These anti-CD38 monoclonal antibodies will be blockbuster drugs and an important component of multiple myeloma treatment. (ascopost.com)
An investigational class of agents in multiple myeloma, the anti-CD38 monoclonal antibodies, could be the next blockbusters in this malignancy, myeloma experts predicted at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. (ascopost.com)
Anti-CD38 antibodies target multiple myeloma cells by binding to the CD38 antigen expressed on the cell surface and then signaling the patient's immune system to attack the tumor. (ascopost.com)
These anti-CD38 monoclonal antibodies, I believe, will be blockbuster drugs and an important component of multiple myeloma treatment," he predicted. (ascopost.com)
[00:00:00] In recent years, a monoclonal antibody called daratumumab has emerged as a new treatment option for relapsed or refractory multiple myeloma. (medmastery.com)
Daratumumab is directed against the antigen CD38, which is highly expressed in myeloma cells. (medmastery.com)
14 August 2023 - Today, the FDA granted accelerated approval to elranatamab-bcmm (Elrexfio, Pfizer), a bispecific B-cell maturation antigen directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (maestrodatabase.com)
10 August 2023 - On 9 August 2023, the FDA granted accelerated approval to talquetamab-tgvs (Talvey, Janssen Biotech) for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (maestrodatabase.com)
Pfizer), a bispecific B-cell maturation antigen-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 previous lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. (oncpracticemanagement.com)
Janssen Biotech), a bispecific GPRC5D-directed CD3 T-cell engager, for the treatment of adults with relapsed or refractory multiple myeloma who have previously received at least 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. (oncpracticemanagement.com)
Multiple myeloma (MM), a clonal expansion of plasma cells, is characterised by monoclonal protein production, end-organ damage and marked clinical and genetic heterogeneity. (touchoncology.com)
CARTITUDE-1 was a Phase 1b/2 open-label, multicenter study evaluating the efficacy and safety of a single infusion of ciltacabtagene autoleucel in adult patients with relapsed or refractory multiple myeloma who had previously received a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (carvyktihcp.com)
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. (carvyktihcp.com)
Abecma was approved by the U.S. Food and Drug Administration (FDA) in March 2021 for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. (bms.com)
CHICAGO, June 3, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of TECVAYLI ® (teclistamab-cqyv), a first-in-class BCMAxCD3 bispecific antibody, and talquetamab, a first-in-class GPRC5DxCD3 bispecific antibody, showing a high overall response rate (ORR) among patients with relapsed or refractory multiple myeloma (RRMM). (jnj.com)
1 These results underscore the potential combinability of these two novel bispecific therapies, which target distinct antigens on myeloma cells. (jnj.com)
By combining teclistamab and talquetamab, two bispecific antibodies that have demonstrated high efficacy responses in targeting distinct antigens, we evaluated the potential of this unique combination regimen for patients who were resistant or refractory to multiple lines of therapy," said Yael Cohen, M.D., Head of Myeloma Unit, Hematology Institute, Tel-Aviv Sourasky Medical Center, Israel, and principal study investigator. (jnj.com)
Virtually all MM cases begin as the pre-malignant plasma cell disorders monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM) and usually neither of them presents with symptoms. (lls.org)
Currently, one project in the SCOR grant of Robert Z. Orlowski, M.D., Ph.D. ( MD Anderson ) is a multi-center clinical trial of isatuximab in high-risk smoldering myeloma (SMM) exploring the use of this monoclonal anti-CD38 antibody in the precursor disease of MM. (lls.org)
Multiple myeloma (MM) is the second most common hematologic malignancy and remains incurable despite the advent of numerous new drugs such as proteasome inhibitors (PIs), immunomodulatory agents (IMiDs), and monoclonal antibodies. (biomedcentral.com)
Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of transformed monoclonal plasma cells in the bone marrow (BM) [ 1 ]. (biomedcentral.com)
Dr. Francesca Cottini explains the role of bispecific antibody therapy and CAR T-cell therapy and how these emerging therapies are changing myeloma care. (powerfulpatients.org)
CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo. (moleculardepot.com)
5: Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG 3rd, Liu B. The development of potential antibody-based therapies for myeloma. (moleculardepot.com)
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. (moleculardepot.com)
CD38 - /CD138 - negative multiple myeloma. (moleculardepot.com)
This transaction, if finalized, would expand upon the COEP collaboration with VyGen-Bio, which is currently focused on CD38-GEAR-NK, a natural killer (NK) cell therapy for the treatment of CD38+ cancers with an initial focus on multiple myeloma, and CD38-Diagnostic, an in vitro diagnostic tool being developed to help identify cancer patients who may be appropriate candidates for anti-CD38 mAb therapy. (thepilotnews.com)

MM always follows the premalignant state of monoclonal gammopathy of undetermined significance (MGUS), although the precise molecular mechanisms involved in the progression from MGUS to MM are not properly understood. (touchoncology.com)

Examples include daratumumab (Darzalex) and isatuximab (Sarclisa) for CD38 proteins, or elotuzumab ( Empliciti ) for SLAMF7 proteins. (healthline.com)
and an anti-CD38 monoclonal antibody, such as Darzalex ® (daratumumab). (vativorx.com)
such as chemotherapy, proteasome inhibitors (Bortezomib, Carfilzomib and Ixazomib), immunomodulatory IMiDs (Thalidomide, Lenalidomide and Pomalidomide), Histone deacetylase (HDAC) inhibitors (Panobinostat) and monoclonal antibodies (Daratumumab, Elotuzumab and Isatuximab). (lls.org)
e.g., thalidomide, lenalidomide, and pomalidomide), and monoclonal antibodies (e.g., daratumumab and elotuzumab) has provided numerous therapeutic avenues for patients with MM. Despite these advanced therapies, most MM patients eventually relapse and become resistant to treatment, and the length and depth of response to therapies typically decrease in the following relapse. (biomedcentral.com)

Now we have game-changing T-cell-redirecting therapies, such as CAR [chimeric antigen receptor] T-cell therapies and bispecific antibodies," he explained. (onclive.com)
The most exciting current experimental therapies and trials in MM focus on immunotherapies: novel monospecific antibodies (such as isatuximab), bispecific antibodies (BiTEs), drugs that are linked to antibodies (ADCs) and CAR-T! (lls.org)
There is an unmet need to develop novel therapies for refractory/relapsed MM. In the past few years, chimeric antigen receptor (CAR)-modified T cell therapy for MM has shown promising efficacy in preclinical and clinical studies. (biomedcentral.com)
Current CAR T therapies are designed to target specific tumor antigens that correspond to a specific cancer indication. (vizrelease.com)
Dr. Ashley Rosko outlines the factors that impact treatment decisions and reviews available therapies including stem cell transplant, proteasome inhibitors, immunomodulatory therapies, and monoclonal antibodies. (powerfulpatients.org)

The COEP product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which COEP is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. (vizrelease.com)

SNAP-CAR, which COEP licensed from the University of Pittsburgh, is a multi-antigen chimeric antigen receptor T cell (CAR T) technology that can be adapted to different cancer indications, including hematologic and solid tumors. (vizrelease.com)

Description: The 90 monoclonal antibody reacts with the mouse CD38 molecule, an ~42 kDa type II transmembrane protein. (thermofisher.com)
Human CD38, a surface molecule expressed by immature and activated T and B lymphocytes, has been characterized as a molecule transducing activation and proliferation signals, and intervening in adhesion to endothelium via its ligand CD31. (nih.gov)
We investigated the effects of monocyte-activating stimuli (IFN-gamma, IL-2, LPS, TNF-alpha, and GM-CSF) on the expression and function of CD38, starting from the observation that human monocytes and the derived lines U937, THP-1, and Mono-Mac-6 bear the molecule on their surface. (nih.gov)
Description: The RPA-T8 monoclonal antibody reacts with the human CD8a molecule, an approximately 32-34 kDa cell surface receptor expressed either as a heterodimer with the CD8 beta chain (CD8 alpha/beta) or as a homodimer (CD8 alpha/alpha). (thermofisher.com)
The MEC13.3 antibody specifically recognizes CD31, also known as PECAM-1 (Platelet Endothelial Cell Adhesion Molecule-1). (bdbiosciences.com)

Crosslinking of CD38 on the surface of mature, resting B cells induces B-cell proliferation, which is enhanced by co-signals such as IL-4 and LPS. (thermofisher.com)
CD38 induces production of proinflammatory cytokines and proliferation. (biolegend.com)

It is a bispecific humanized monoclonal antibody against CD3, a T-cell surface antigen, and GPRC5D (human G-protein coupled receptor family C group 5 member D), a tumor-associated antigen with potential antineoplastic activity. (medscape.com)
HER2 is a tumor-associated antigen (TAA) that is overexpressed in approximately 28%1 of ovarian cancer tissues and 25% of patients with breast cancer2. (vizrelease.com)

CD38, a counter-receptor for CD31, is an ectoenzyme with cyclase and hydrolase enzymatic activity and is speculated to play a role in lymphocyte activation and differentiation. (thermofisher.com)
The ligand for CD38 is CD31. (biolegend.com)
Left Panel) or BD Horizon™ BV510 Rat Anti-Mouse CD31 antibody (Cat. (bdbiosciences.com)

Immunoprecipitation of CD38 protein from mouse spleen tissue extracts. (cellsignal.com)
A poignant reminder here was the disastrous peripheral nerve damage experienced by women with breast cancer treated with a ricin A chain-based immunotoxin which unexpectedly also targeted nervous tissue.4 The most sensitive in vitro method for determining the selective cytotoxic potency of saporin-based immunotoxins is by measuring their ability to selectively inhibit protein synthesis in antigen-expressing cell lines in a dose-dependent manner. (atsbio.com)
This is clearly shown in Figure 2, where increasing concentrations of two immunotoxins: anti-CD19 (BU12-Saporin) and anti-CD38 (OKT10-SAP) show decreasing protein synthesis levels in a target CD19+ CD38+ pediatric acute lymphoblastic leukaemia (ALL) cell line. (atsbio.com)
Ligation of MHC-I/peptide complexes presented by antigen-presenting cells (APCs), triggers the recruitment of lymphocyte-specific protein tyrosine kinase (Lck), which leads to lymphokine production, motility and cytotoxic T lymphocyte (CTL) activation. (thermofisher.com)
CD38 is a 45 kD type II transmembrane protein. (biolegend.com)
For several reasons there is a growing interest in the scientific community in immunoglobulin Y as antibiotic alternative and their oral administration in the polyclonal antibody (pAb) format, to maintain animal health and performance, do not require IgY purification for large-scale production, resulting in protein impurities and high concentration of biotin in the samples. (preprints.org)
This importance is focussed on the target binding site - epitope, where epitope selection as a part of design thinking beyond traditional antigen selection using whole cell or whole protein immunisation can positively impact success. (preprints.org)
With purified recombinant protein production and peptide synthesis to display limited/selected epitopes, intrinsic factors that can affect the functioning of resulting antibodies can be more easily selected for. (preprints.org)
Chimeric antigen receptor (CAR) T cell therapy has emerged as a novel immunotherapy which modifies T cells with CAR, an artificial fusion protein that incorporates an extracellular antigen recognition domain, a transmembrane domain, and an intracellular domain including costimulation and signaling components [ 4 , 5 ]. (biomedcentral.com)
CD138 Antibody (Rabbit Monoclonal) is a highly pure antibody that recognizes a synthetic peptide derived from internal region of human calponin-1 protein. (moleculardepot.com)

Long-Lived Plasma Cells Are Contained within the CD19(-)CD38(hi)CD138(+) Subset in Human Bone Marrow. (moleculardepot.com)

Traditional polyclonal and monoclonal antibodies are the product of normal B cell development and genetic recombination. (cellsignal.com)
While polyclonal antibodies are secreted by many different B cell clones and recognize multiple antigenic epitopes, monoclonals originate from a single B cell clone and are specific for just one epitope. (cellsignal.com)
Where polyclonal antibodies are purified directly from the serum of the immunized host, and monoclonals are purified from either hybridoma-derived tissue culture supernatant or ascites, recombinant antibodies are instead purified from the tissue culture supernatants of transfected host cell lines. (cellsignal.com)
Regardless of whether an antibody is polyclonal, monoclonal or recombinant, it must always be properly validated in the intended application prior to experimental use. (cellsignal.com)

CD38 is expressed at increasingly higher levels on B cells at each stage of B-cell differentiation, and is then down-regulated on germinal center B cells and mature plasma cells. (thermofisher.com)
CD38 (NAD+ glycohydrolase) is a type II transmembrane glycoprotein able to induce activation, proliferation and differentiation of mature lymphocytes and mediate apoptosis of myeloid and lymphoid progenitor cells. (thermofisher.com)
Antibodies to CD38 are useful in subtyping of lymphomas and leukemias, detection of plasma cells (i.e. identification of myelomas), and as a marker for activated B and T cells. (thermofisher.com)
These man-made antibodies may help attack proteins on the surface of multiple myeloid cells. (healthline.com)
The abnormal plasma cells produce abnormal antibodies, which can cause kidney problems and overly thick blood. (wikipedia.org)
Chimeric antigen receptors (CARs) are synthetic proteins expressed on the surface of T cells. (medscape.com)
We examined the CD45 dim CD34 + CD38 - CD133 + cells on bone marrow samples of hematologic malignancies and healthy controls using four-color flow cytometry experiments. (researchsquare.com)
Interestingly, the CD45 dim CD34 + CD38 - CD133 + cells were highly expressed in bone marrow of patients with AML compared to that of healthy controls (HC). (researchsquare.com)
Additionally, the high levels of the CD45 dim CD34 + CD38 - CD133 + cells in AML patients were an independently significant poor risk factor for overall survival and event free survivals. (researchsquare.com)
Therefore, our results suggest that CD45 dim CD34 + CD38 - CD133 + cells in AML might have the potential of leukemia stem cells. (researchsquare.com)
For examples, Rhenen et al showed that a high percentage of CD34 + CD38 - stem cells at diagnosis significantly correlated with a high minimal residual disease frequency and subsequently to relapse especially after the third course of chemotherapy in AML patients. (researchsquare.com)
Moreover, the CD34 + CD38 - progenitor cells expressed variable amounts of the target receptor CD33, CD133 and c-kit (CD117) [ 20 ]. (researchsquare.com)
However, CD38 is also weakly expressed on red blood cells. (medmastery.com)
[00:00:30] It interferes with reagent and donor blood cells used in antibody screening as well as in crossmatching and also may affect the results of a direct antiglobulin test. (medmastery.com)
Before performing any lab tests, the lab staff will then treat both the test and donor cells with the special chemical called DTT, which destroys CD38 on the cells. (medmastery.com)
Applications Tested: This RPA-T8 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. (thermofisher.com)
Accordingly, here we analyse antibodies and T cells of a recently vaccinated, UK cohort, alongside those recovering from natural infection in early 2020. (nature.com)
Their modifications include adding a chimeric antigen receptor specific for B7-H3 and partnering with Fate Therapeutics to make four genetic modifications to these cells. (urotoday.review)
What we've done is we've been able to engineer natural killer cells and then we've added a chimeric antigen receptor specific for B7-H3. (urotoday.review)
We have a couple of other modifications that we've been able to make with our therapeutic partners as well, Fate Therapeutics, and that includes high affinity CD-16 that allows us to add a second monoclonal antibody to redirect the cells as well to give it a second kill signal. (urotoday.review)
A type of white blood cell found in bone marrow, plasma cells are matured B cells that produce antibodies. (vativorx.com)
CD38 is a 45 kD type II transmembrane ADP-ribosyl cyclase expressed on early hematopoietic precursors and leukocytes, hepatic stellate cells, astrocytes and epithelial cells. (biolegend.com)
To maximize performance, it is strongly recommended that the reagent be titrated for each application, and that you centrifuge the antibody dilution before adding to the cells at 14,000xg at 2 - 8°C for 10 minutes. (biolegend.com)
This disease is characterized by the uncontrolled proliferation of abnormal monoclonal plasma cells in the bone marrow. (lls.org)
Focused on SNAP-CAR T Cells, a Platform Technology Being Developed to be Combined with Tagged, Tumor-Specific Antibodies to Potentially Target Many Different Tumor Types. (vizrelease.com)
Modified NK cells that are co-administered with select monoclonal antibodies and/or other CD38 targeting immunotherapies are in pre-clinical development to enhance and maximize tumor kill via combinatorial approaches otherwise not possible. (vizrelease.com)
So, these two strategies, CAR T and bispecific antibodies, really rely on the T-cells, on the immune cells of the patient. (powerfulpatients.org)
So, at the same time that I am able to get close by the T cells, the immune cells, and in this way, practically there is both the antibodies and also the immune cells which is activating and getting rid of the cancer cells. (powerfulpatients.org)
Bone marrow cells were stained with APC Rat Anti-Mouse CD45R/B220 antibody (Cat. (bdbiosciences.com)
The B cells become continuously activated by acquisition of mutations that lead to monoclonal B-cell lymphocytosis (MBL). (msdmanuals.com)
Further accumulation of genetic abnormalities and subsequent oncogenic transformation of monoclonal B cells leads to CLL. (msdmanuals.com)

Lane 1 is 10% input, lane 2 is Rabbit (DA1E) mAb IgG XP ® Isotype Control #3900, and lane 3 is CD38 (E9F5A) XP ® Rabbit mAb. (cellsignal.com)
Immunohistochemical analysis of paraffin-embedded mouse spleen using CD38 (E9F5A) XP ® Rabbit mAb (left) compared to concentration-matched Rabbit (DA1E) mAb IgG XP ® Isotype Control #3900 (right). (cellsignal.com)
Mouse anti-human CD45-FITC (Clone 2D1, Cat No. 347463), Mouse Anti-human CD34-PE [Clone 8G12 (also known as HPCA2), Cat No. 348057], Mouse anti-human CD38-PE-Cy™5 (Clone HIT2, Cat No. 555461) and appropriated isotype control antibodies were purchased from BD Biosciences (San Diego, CA, USA). (researchsquare.com)
An isotype control should be used at the same concentration as the antibody of interest. (bdbiosciences.com)

Chronic lymphocytic leukemia (CLL) is a monoclonal disorder characterized by a progressive proliferation and accumulation of mature yet functionally incompetent lymphocytes. (medscape.com)
Classical monocyte proliferation and CD38 upregulation on plasmacytoid DCs coincided with declining viral load. (cdc.gov)

Applications Reported: This 90 antibody has been reported for use in flow cytometric analysis. (thermofisher.com)
Applications Tested: This 90 antibody has been tested by flow cytometric analysis of mouse splenocytes. (thermofisher.com)
Applications Reported: This RPA-T8 antibody has been reported for use in flow cytometric analysis. (thermofisher.com)
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis and the oligomer sequence is confirmed by sequencing. (biolegend.com)

The importance of our analysis is the demonstration that efficient therapeutic remedies of a number of related influenza varieties (H1N1, H3N2, and B) may be achieved by airway administration of a single mixture of comparatively small quantities of three anti-influenza antibodies . (bd-academy.org)
This advance exploits the invention that airway supply is a stronger manner of administering anti-influenza antibodies in comparison with systemic supply, making this a possible and cost-effective therapeutic method. (bd-academy.org)
Additional development options that would be explored could include therapeutic modalities where the antigen-specificity of mAbs is used, such as CAR-T and bispecific antibodies for the treatment of a broad range of hematologic malignancies and solid tumors. (thepilotnews.com)
Participant has previous history of an allogeneic hematopoietic stem cell transplantation or treatment with any gene therapy-based therapeutic for cancer or investigational cellular therapy for cancer or B-cell maturation antigen targeted therapy. (who.int)

They are generated by immunizing an animal with an antigen to elicit an immune response. (cellsignal.com)
Scientists have screened neutralizing antibodies utilizing the virus receptor-binding area (RBD) as an antigen, indicating that RBD accommodates a number of conformational neutralizing epitopes, that are the primary structural domains for inducing neutralizing antibodies and T-cell immune responses. (bd-academy.org)
As a result of influenza vaccination may be poorly efficient some years, and the immune system of probably the most prone populations are sometimes compromised, passive immunization remedies utilizing broadly- neutralizing antibodies is a promising therapeuti c method. (bd-academy.org)
B.1.617.2 (Delta) was first isolated in India and also shows some evidence of immune escape, specifically from neutralizing antibodies, but to a lesser degree than B.1.351 7 . (nature.com)
TotalSeq™-C antibodies are compatible with 10x Genomics Chromium Single Cell Immune Profiling Solution . (biolegend.com)
We observed that age advancement in all three groups combined was associated with a monocyte immune phenotypic profile related to inflammation and a T cell immune phenotypic associated with immune senescence and chronic antigen exposure. (frontiersin.org)
The T cell immune phenotypic profile in blood donors was related to loss of T cell function, whereas the same set of markers were related to chronic antigen stimulation and immune senescence in HIV-negative individuals. (frontiersin.org)
The identified monocyte and T cell immune phenotypic profiles that were associated with age advancement, were strongly related to inflammation, chronic antigen exposure and immune senescence. (frontiersin.org)

Recombinant antibodies are monoclonal, but their production involves in vitro genetic manipulation. (cellsignal.com)
In vitro methods for producing antibodies are amenable to large-scale production, meaning antibody availability is unlikely to become a limiting factor. (cellsignal.com)

CD38 functions as a multi-catalytic ectoenzyme serving as ADP-ribosyl cyclase, cyclic ADP-ribose hydrolase and possibly NAD+ glycohydrolase or as a cell surface receptor. (thermofisher.com)
CD38 is also a complex ectoenzyme featuring ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase activities, leading to the synthesis and degradation of cADPR, a Ca+-mobilizing agent. (nih.gov)
Treatment with IFN-gamma produced a dose- and time-dependent up-regulation of CD38 in monocytes and monocytic lines, which was paralleled by increased ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase activities. (nih.gov)

The COEP CD38 Diagnostic is designed to be used as a companion with CD38 GEAR-NK or as a standalone diagnostic screening test to determine which immunotherapies may be responsive to CD38+ tumors. (vizrelease.com)

Many of these factors stem from the location of the epitope that can affect accessibility of the antibody to the epitope at a cellular or molecular level, direct inhibition of target antigen activity, conservation of function despite escape mutations, and even non-competitive inhibition sites. (preprints.org)

Our data confirm that VOC, particularly those such as B.1.351 with substitutions at residues 484 and 417, escape neutralization by antibodies directed to the ACE2-binding Class 1 and the adjacent Class 2 epitopes but are susceptible to neutralization by the generally less potent antibodies directed to Class 3 and 4 epitopes on the flanks of the RBD. (nature.com)

The following product was used in this experiment: CD38 Monoclonal Antibody (90), eFluor™ 450, eBioscience™ from Thermo Fisher Scientific, catalog # 48-0381-82, RRID AB_11218302. (thermofisher.com)
The following product was used in this experiment: CD8a Monoclonal Antibody (RPA-T8), eFluor™ 450, eBioscience™ from Thermo Fisher Scientific, catalog # 48-0088-42, RRID AB_1272062. (thermofisher.com)

Impairment in CD38 expression is associated with immunological and behavioral disorders. (biolegend.com)

Must have received at least 3 or more lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory imide drug (IMiD), and an anti-CD38 monoclonal antibody. (survivornet.com)
Participant must have received 4 to 6 cycles of induction therapy, which must contain at a minimum an immunomodulatory drugs (IMiD) and a proteasome inhibitor (PI) (with or without anti-CD38 monoclonal antibody) and must have had a single ASCT 80 to 120 days prior to consent. (who.int)

Furthermore, CD38 ligation by specific MoAb reduced the IFN-gamma-dependent enhancement of monocyte-dynamic adhesion to endothelial monolayers. (nih.gov)

Diseases associated with CD38 dysfunction include chronic lymphocytic leukemia and Richter's Syndrome. (thermofisher.com)
Chronic lymphocytic leukemia (chronic lymphoid leukemia, CLL) is a monoclonal disorder characterized by a progressive accumulation of functionally incompetent lymphocytes (see the image below). (medscape.com)

CD38 participates in cell adhesion, signal transduction and calcium signaling. (thermofisher.com)

Increased class 1 HDAC expression has been linked in solid tumours with more locally advanced, de-differentiated and proliferative tumours, and with poor prognosis in MM. HDAC inhibitors, panobinostat and ricolinostat, have been demonstrated to be effective in combination with bortezomib and dexamethasone in newly diagnosed patients with MM and in heavily pre-treated patients with advanced MM. HDAC inhibitor-monoclonal antibody combinations are also being explored. (touchoncology.com)

The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. (bdbiosciences.com)

Anatomy27

Organisms11

Diseases5

Chemicals and Drugs143

Analytical, Diagnostic and Therapeutic Techniques and Equipment39

Phenomena and Processes35

Disciplines and Occupations2

Information Science3

Health Care2

BCMA9

Myeloma33

Gammopathy of undetermined significance1

Daratumumab4

Therapies5

Multi-antigen CAR T technology1

Chimeric antigen receptor T-cell1

Molecule5

Induces2

Tumor-associated antigen2

CD313

Protein10

CD191

Polyclonal4

Cells31

Isotype Control4

Proliferation2

Flow cytometric analysis4

Therapeutic4

Immune8

Vitro2

Cyclase3

Immunotherapies1

Epitope1

Epitopes1

EFluor2

Impairment1

IMiD2

Monocyte1

Chronic2

Cell adhesion1

HDAC1

Tissue1